Advanced Tissue biomaterial/skin/wound news

ATIS will discontinue sales of its Skin2 living human skin tissue to focus on its therapeutic products. ATIS said Skin2 had been used primarily by cosmetic and household goods companies for in vitro testing of materials and compounds for eye and skin irritation, but that the market for the service had developed slowly. For the six months ended June 30, Skin2 posted sales of $655,000. The service had employed 18 people, most of whom have been transferred to the company's Dermagraft programs. ATIS's Dermagraft-TC is under FDA review for severe burns, and the company expects to submit a PMA for Dermagraft for diabetic foot ulcers this year. ...